Cas:526-83-0 L-(+)-Tartaric acid manufacturer & supplier

Chemical Name:L-(+)-Tartaric acid

CAS.NO:526-83-0

Synonyms:L-(+)-Tartrate;(2R,3R)-(+)-Tartaric acid;(+)-tartaric acid;(2R,3R)-2,3-Dihydroxysuccinic acid;(R,R)-(+)-tartaric acid;D(-)-Tartaric acid;(2R,3R)-2,3-dihydroxybutanedioic acid;Ordinary Tartaric Acid;Tartaric acid;L-(+)-Tartarate;Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-rel-;DL-Tartaric acid;L-tartaric acid;UNII:4J4Z8788N8;(+)-L-tartaric acid;[R-(R*,R*)]-2,3-Dihydroxybutanedioic Acid;(+)-(R,R)-tartaric acid;(2R,3R)-tartaric acid;Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-;L-2,3-Dihydroxybutanedioic Acid;Tartarate;(R,R)-tartaric acid;(+)-(2R,3R)-Tartaric acid

Molecular Formula:C₄H₆O₆

Molecular Weight:150.087

HS Code:2918120000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:399.3±42.0 °C at 760 mmHg

Density:1.9±0.1 g/cm3

Index of Refraction:1.586

PSA:115.06000

Exact Mass:150.016434

LogP:-1.43

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like L-(+)-Tartrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(+)-(2R,3R)-Tartaric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[R-(R*,R*)]-2,3-Dihydroxybutanedioic Acid Use and application,DL-Tartaric acid technical grade,usp/ep/jp grade.

Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. L-(+)-Tartaric acid manufacturer Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData��s Company Financials database. L-(+)-Tartaric acid supplier Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. L-(+)-Tartaric acid vendor Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData��s Company Financials database. L-(+)-Tartaric acid factory It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.